Navigation Links
Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)

Unique monoclonal antibody successfully targets human leukemic stem cells

ATLANTA, Dec. 10 /PRNewswire/ -- CSL Limited, Australia's leading biopharmaceutical company, has today presented data at the American Society of Hematology (ASH) 49th annual meeting, which demonstrate the promising pre-clinical activity of a novel monoclonal antibody, in the potential treatment of acute myeloid leukemia (AML).

AML is an aggressive cancer of white blood cells and most commonly occurs in adults. It is usually treated with chemotherapy but the cure rate in adults is only about 30%. About 9,000 deaths from AML occur each year in the United States(1). The novel antibody specifically targets the "core cell" of AML, called the leukemic stem cell (LSC) which was first identified in the laboratory of Professor John Dick, one of the key authors of the study(2). It is currently thought that the resistance of leukemic stem cells to chemotherapy is a major reason for the inability to cure most AML, and that improving the outlook for patients with AML will require elimination of these cells.

The antibody used in the research, called 7G3, was first created by Dr Angel Lopez at the Hanson Centre for Cancer Research in Adelaide, South Australia. It hones in on CD123 (IL-3 receptor alpha chain) on the surface of the LSC, blocking its function, growth and survival. CD123 is found on the surface of normal blood stem cells much less frequently, and 7G3 should therefore have no effect on normal blood cell development.

The research presented at the ASH meeting by key investigator Associate Professor Richard Lock of Children's Cancer Institute Australia for Medical Research in Sydney, describes the results of treatment with 7G3 of irradiated immune-deficient mice with AML.

Two central experiments were undertaken; firstly human AML stem cells were treated with 7G3 and then injected into the mice, which were compared with a control group of mice injected with untreated AML stem cells. The overall survival of treated engrafted mice was significantly improved with the median survival of control group 11.5 weeks versus 24 weeks for the antibody-treated group.

Secondly, 7G3 was administered to mice with established AML. Administration of the antibody to these mice reduced AML dissemination around the body of the mice. The ability of leukemic stem cells from mice treated in this way to reestablish leukemia as secondary transplants into other animals was markedly reduced.

In contrast, exposure to 7G3 had little effect on normal human bone marrow stem cells.

"These results show that 7G3 is able to target LSC's to prevent them from moving around and proliferating in the mice, while at the same time having little effect on normal blood cells," said Dr Lock at the ASH meeting today.

"This is a very exciting finding because it is one of the first drugs that has been designed to specifically target the LSC, rather than simply attacking the cancer cells proliferating in the blood and bone marrow. Hopefully this means that it can fight leukemia without many of the side effects of current drugs. It opens up an exciting new option for the treatment of AML," he said.

CSL wishes to acknowledge the contribution of the University Health Network in Toronto, Canada, The Institute of Medical and Veterinary Science/Hanson Institute for Cancer Research in South Australia, Children's Cancer Institute Australia for Medical Research in Sydney, Australia and the Queensland Institute for Medical Research, Australia, its key collaborators in this important project.

For further information please contact:

Associate Professor Richard Lock

Head, Leukaemia Biology Program

Children's Cancer Institute Australia for Medical Research

Phone: +61 414 769 194

Dr. Darryl Maher

Medical Director

CSL Bioplasma

Phone: +61 412 346 987

Media Contact

Sheila A. Burke OR Jeff Hoyak

Director, Communications & Public Relations MCS Public Relations

Worldwide Commercial Operations, CSL Behring +1-908-884-6753


Media Contact - Australia only

Dr Rachel David

Director of Public Affairs

CSL Limited

Phone: +61 401 775 779

(1) American Cancer Society, Cancer Reference Information.

(2) Lapidot et al Nature 1994

Bonnet & Dick Nature Medicine August 31, 1997.

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from reveals that behind the tendency to ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):